13.03.2022, 2739 Zeichen

Austrian Post: Group revenue of Austrian Post rose by 14.9 % in 2021 to Euro 2,519.6 mn , of which 5.7 % is attributable to organic growth and the remainder to the full consolidation of the Turkish subsidiary Aras Kargo. Following strong pandemic-driven momentum in the parcel business during the first three quarters there was a consolidation in the fourth quarter. Fourth quarter 2021 parcel revenue was up by 0.9 % from the previous period. The basic trends impacting current business activities were also visible in 2021 i.e., declining letter mail and direct mail volumes accompanied by a simultaneous increase in parcel volumes also triggered by lockdown-related closures of retail stores. EBITDA increased to Euro 370.4 mn (+22.3 %) and earnings before interest and tax (EBIT) rose by 27.5 % to Euro 204.7m. Based on good results, a dividend of Euro 1.90 per share will once again be proposed to the Annual General Meeting scheduled for 21 April 2022. From today's perspective, a challenging environment is anticipated in the 2022 financial year as well as the non-recurrence of positive pandemic-related one-off effects. Delays in the global value chain and rising inflation already took place in 2021 alongside pressure on the Turkish lira. The current political events pose major challenges to the European population and companies, the company statet. For the current year Austrian Post aims to keep revenues as stable as possible and operating earnings (EBIT) once again close to the prior-year level.
Österreichische Post: weekly performance: -1.46%

Valneva: Valneva SE, an Austrian/French specialty vaccine company, today provided an update on the regulatory review of its inactivated, COVID-19 vaccine candidate, VLA2001, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). As announced on February 25, 2022, Valneva received a list of questions as part of the CHMP’s initial assessment to which it responded within two working days. Valneva has now received a small set of additional questions and is confident it will be able to respond to these in the coming days. With this additional round of questions and a tentative timetable also received from the EMA, and subject to the CHMP’s acceptance of Valneva’s responses, Valneva now anticipates receiving a positive CHMP recommendation for conditional approval of VLA2001 for primary immunization in adults 18 to 55 years of age in April 2022. Following such conditional approval, the Company would expect to start delivering planned doses of VLA2001 to European countries in the second quarter of 2022.
Valneva: weekly performance: 12.98%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (11/03/2022)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1135: ATX leicht schwächer, Wienerberger Heavyweight und Geburtstagskind, Strabag mit mehr Streubesitz

Bildnachweis

Aktien auf dem Radar:Rosenbauer, Österreichische Post, RBI, Semperit, EuroTeleSites AG, FACC, Amag, Bajaj Mobility AG, Bawag, Frequentis, CA Immo, Erste Group, EVN, Verbund, Strabag, BKS Bank Stamm, Athos Immobilien, BTV AG, Oberbank AG Stamm, CPI Europe AG, Telekom Austria, Infineon, Merck KGaA, Siemens Healthineers, Fresenius Medical Care, SAP, Allianz, Münchener Rück, Zalando, Deutsche Telekom, DAIMLER TRUCK HLD....

---